Abstract
Conditionally replicative adenoviruses (CRAds) are often evaluated in mice; however, normal and cancerous mouse tissues are poorly permissive for human CRAds. As the cotton rat (CR) is a semipermissive animal and the Syrian hamster (SH) is a fully permissive model for adenoviral replication, we compared them in a single study following intracranial (i.c.) injection of a novel glioma-targeting CRAd. Viral genomic copies were quantified by real-time PCR in brain, blood, liver and lung. The studies were corroborated by immunohistochemical, serological and immunological assays. CR had a multiple log higher susceptibility for adenoviral infection than SH. A similar amount of genomic copies of CRAd-Survivin-pk7 and human adenovirus serotype 5 (AdWT) was found in the brain of CR and in all organs from SH. In blood and lung of CR, AdWT had more genomic copies than CRAd-Survivin-pk7 in some of the time points studied. Viral antigens were confirmed in brain slices, an elevation of serum transaminases was observed in both models, and an increase in anti-adenoviral antibodies was detected in SH sera. In conclusion, CR represents a sensitive model for studying biodistribution of CRAds after i.c. delivery, allowing for the detection of differences in the replication of CRAd-Survivin-pk7 and AdWT that were not evident in SH.
Similar content being viewed by others
References
Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J . Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 2006; 6: 697–708.
Sonabend AM, Ulasov IV, Han Y, Lesniak MS . Oncolytic adenoviral therapy for glioblastoma multiforme. Neurosurg Focus 2006; 20: E19.
Ulasov IV, Tyler MA, Han Y, Glasgow JN, Lesniak MS . Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther 2007; 18: 118–129.
Tyler MA, Ulasov IV, Borovjagin A, Sonabend AM, Khramtsov A, Han Y et al. Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Mol Cancer Ther 2006; 5: 2408–2416.
Sebestyen Z, de Vrij J, Magnusson M, Debets R, Willemsen R . An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res 2007; 67: 11309–11316.
Wohlfahrt ME, Beard BC, Lieber A, Kiem HP . A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 2007; 67: 8783–8790.
Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM et al. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. Int J Oncol 2007; 31: 1177–1185.
Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 2006; 104: 583–592.
Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 2007; 6: 679–685.
Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2–12.
Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.]. Ai Zheng 2004; 23: 1666–1670.
Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98: 298–300.
Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007; 18: 589–602.
Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, Lesniak MS . Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007; 9: 151–160.
Nandi S, Ulasov IV, Tyler M, Sugihara AQ, Molinero L, Han Y et al. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 2008; 68: 5778–5784.
Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1991; 88: 1651–1655.
Hjorth RN, Bonde GM, Pierzchala WA, Vernon SK, Wiener FP, Levner MH et al. A new hamster model for adenoviral vaccination. Arch Virol 1988; 100: 279–283.
Duncan SJ, Gordon FC, Gregory DW, McPhie JL, Postlethwaite R, White R et al. Infection of mouse liver by human adenovirus type 5. J Gen Virol 1978; 40: 45–61.
Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16: 139–146.
Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270–1276.
Toth K, Spencer JF, Wold WS . Immunocompetent, semi-permissive cotton rat tumor model for the evaluation of oncolytic adenoviruses. Methods Mol Med 2007; 130: 157–168.
Thomas MA, Spencer JF, Wold WS . Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 2007; 130: 169–183.
Hsu W, Lesniak MS, Tyler B, Brem H . Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol 2005; 74: 135–140.
Lesniak MS, Gabikian P, Tyler BM, Pardoll DM, Brem H . Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol 2004; 70: 23–28.
Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H . Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005; 25: 3825–3831.
Zhu ZB, Chen Y, Makhija SK, Lu B, Wang M, Rivera AA et al. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int J Oncol 2006; 29: 1319–1329.
Wu H, Han T, Lam JT, Leath CA, Dmitriev I, Kashentseva E et al. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy. Gene Ther 2004; 11: 874–878.
Graham FL, Smiley J, Russell WC, Nairn R . Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59–74.
Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070–6079.
Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001; 8: 1618–1626.
Lin X, Huang H, Li S, Li H, Li Y, Cao Y et al. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther 2007; 6: 648–653.
Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005; 12: 437–445.
Nemunaitis J, Senzer N, Sarmiento S, Zhang YA, Arzaga R, Sands B et al. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther 2007; 14: 885–893.
Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14: 107–117.
Miller HI . Gene therapy on trial. Science 2000; 287: 591–592.
Acknowledgements
We are grateful to the animal facility at the University of Chicago for their advice and technical support. In addition, we acknowledge the support of Ms Terri Li from the immunohistochemistry facility at the University of Chicago. This work was supported by the National Cancer Institute (R01-CA122930, MSL), the National Institute of Neurological Disorders and Stroke (K08-NS046430, MSL), The Alliance for Cancer Gene Therapy Young Investigator Award (MSL) and the American Cancer Society (RSG-07-276-01-MGO, MSL).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sonabend, A., Ulasov, I., Han, Y. et al. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther 16, 362–372 (2009). https://doi.org/10.1038/cgt.2008.80
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2008.80
- Springer Nature America, Inc.
Keywords
This article is cited by
-
Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters
Journal of Translational Medicine (2016)
-
The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors
Cancer Gene Therapy (2013)
-
The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model
Cancer Gene Therapy (2013)
-
Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model
Cancer Gene Therapy (2012)
-
Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
Molecular Therapy (2010)